$TCBI

TEXAS CAPITAL BANCSHARES INC/TX (TCBI): Results of Operations and Financial Condition

TEXAS CAPITAL BANCSHARES INC/TX (TCBI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a07222026exhibit991.htm EX-99.1 EARNINGS RELEASE Document Exhibit 99.1 INVESTOR CONTACT Jocelyn Kukulka, 469.399.8544 jocelyn.kukulka@texascapital.com Dallas, TX - July 22, 2026 TEXAS CAPITAL BANCSHARES, INC. ANNOUNCES SECOND QUARTER 2026 RESULTS Second quarter 2026 net

Original reporting
Published Jul 22, 2026, 8:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 22, 2026, 8:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$TCBI
Bullish
medium confidence
Mentioned
$TCBI
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$TCBIBullishMed
01

Why it matters

The release updates TCBI’s quarterly earnings, capital ratios, and credit-quality indicators, which can affect valuation multiples and near-term expectations for net interest margin and credit costs.

02

Market read

Fresh quarterly datapoints on EPS, book value, CET1, NIM, and credit-loss provision create a decision point for positioning in TCBI and for regional bank credit/margin expectations.

03

What to watch

Provision drivers include criticized-loan growth and net charge-offs; traders may focus on whether criticized loans continue rising beyond June 30, 2026 rather than the headline EPS beat.

Relevance 7/10Novelty 8/10Timing: after-hours earnings release filed on SEC 8-K (July 22, 2026)

Background

The company filed an SEC 8-K with its Q2 2026 results (Item 2.02) and an attached earnings release (Exhibit 99.1).

Company-level read

Ticker impact

$TCBIBullishMedium confidence
Context

Texas Capital Bancshares reported Q2 2026 net income of $80.6M, up 10% YoY, alongside CET1 of 12.1% and credit-loss provision of $18.0M.

Expected impact

Moderately positive near-term bias as EPS and book value growth plus strong capital ratios offset a higher credit-loss provision.

Evidence & confidence

The filing includes multiple current-quarter datapoints: EPS $1.83 (up from $1.58 YoY), book value per share $77.01 (up 10% YoY), CET1 12.1%, and credit-loss provision $18.0M driven by criticized loans and net charge-offs.

Market effects

Adds another regional bank datapoint on net interest margin pressure (NIM down QoQ) versus fee income strength and credit-cost normalization.

Limited direct regional spillover, but contributes to broader confidence in Texas/US regional bank credit performance.

Low global relevance; primarily impacts US regional bank sentiment and credit-risk pricing.

Counterpoint

Despite YoY EPS growth, QoQ net interest margin fell to 3.28% and the credit-loss provision rose, which could signal margin and credit headwinds into the back half.

Key entities

  • Texas Capital Bancshares, Inc.

    Reported Q2 2026 results including net income, EPS, capital ratios, and credit-loss provision.

  • Rob C. Holmes

    Chairman, President and CEO quoted on improving financial performance and momentum.

Related articles

$IPHAMed

Innate Pharma (IPHA) Q2 2026 Earnings Call Transcript

Innate Pharma (IPHA) reported Q2 2026 earnings, highlighting a cash position of -€21.4M, a $75M upfront payment from Sobi, and -€28M in net equity proceeds. H1 2026 net loss was -€19.6M, with revenue of -€5.7M. The company extended its cash runway to Q1 2028 and anticipates key milestones, including a Phase 3 readout for monalizumab and initial data for IPH4502. Management expects to file for accelerated approval of lacutamab in Sezary Syndrome in H2 2027.

$UPXIMed

Upexi Inc (UPXI) (Q4 2026) Earnings Call Highlights: Massive Solana Treasury Fuels $246

Upexi Inc. (UPXI) reported Q4 2026 earnings, highlighting a $246M net loss driven by digital asset losses. CEO Alan Marshall discussed Solana treasury management, debt restructuring, and cost-cutting efforts. The company holds 2.34M Solana tokens, with staking revenue covering expenses. Management emphasized creative capital allocation and potential expansion in Asian markets through the Hivemind partnership. Stockholders' equity was negative $53.8M as of June 30, 2026.

$RBAMedAI 8/10

RB Global’s (RBA) Earnings Jump While Its Take Rate Shrinks

RB Global (RBA) reported Q2 earnings with net income up 33% YoY to $132M, EPS up 34% to $0.71, and revenue up 11% to $1.3B. Automotive segment drove GTV growth of 13%. Acquisitions boosted growth, but organic GTV growth was 7%. Service revenue take rate fell 110 bps to 20.0%. Management raised full-year guidance and increased the dividend. Hedge fund ownership declined, and short interest is high at 10.54% of float.

$CRBGMed

A GAAP Loss Masks What Corebridge (CRBG) Actually Earned This Quarter

Corebridge Financial (CRBG) reported a GAAP net loss of $16M for Q2, but adjusted operating income was $512M. Institutional Markets saw strong growth, while Individual Retirement segment declined. The company returned $412M to shareholders and approved a merger with Equitable Holdings. Adjusted pre-tax income fell 21%, and total premiums dropped 13%.